Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2021-04-09 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-04-09 English
News release - English.pdf
Regulatory Filings
2021-03-24 English
News release - English.pdf
Regulatory Filings
2021-03-19 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual and Special Meeting of Shareholders for Revive Therapeutics Ltd. It details the date, time, location, and agenda of the meeting, including receiving audited financial statements, electing directors, appointing auditors, and approving a stock option plan. It also provides instructions for proxy voting and participation via conference call. The document does not contain the actual financial statements or detailed reports but serves as a formal notification and procedural guide for the shareholders' meeting. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length (8457 characters) is sufficient for a detailed notice but does not constitute a full report like an Annual Report or Interim Report. Therefore, the correct classification is AGM Information (AGM-R).
2021-03-09 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Voting Instruction Form (VIF) for an Annual General and Special Meeting scheduled on April 12, 2021. It includes instructions for voting, appointment of proxies, election of directors, appointment of auditors, and approval of a stock option plan. The content is focused on soliciting shareholder votes and providing proxy materials rather than presenting financial data or detailed reports. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI), as it is intended to inform shareholders and solicit their votes for the meeting.
2021-03-09 English
Management information circular - English.pdf
Regulatory Filings
2021-03-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.